semaglutide and cardiovascular outcomes in diabetes Series: outcome trials for drugs SUSTAIN-6 Oral Semaglutide and Cardiovascular Outcomes

Additional Health Benefits Like the injectable version, the Wegovy pill is also FDA-approved to reduce the risk of major adverse cardiovascular events , including cardiovascular death, nonfatal heart attack, or nonfatal stroke, in adults with established cardiovascular disease and obesity or elevated body weight

Studies tracking patients who discontinued semaglutide found that roughly 70% regained most of their lost weight within 12 months without additional lifestyle support or medication

Pregnant or breastfeeding individuals should consult their doctor first Anyone with an allergy to cobalt or B12 should avoid this treatment If you have certain medical conditions, such as Lebers disease (a rare genetic eye disorder), B12 injections may not be suitable This treatment is quick, virtually painless, and can provide an instant energy boost

Individual factors like side effects, cost, and response to treatment determine whether lifelong use makes sense for you specifically